about
Mast cells as effectors in atherosclerosisQuaking promotes monocyte differentiation into pro-atherogenic macrophages by controlling pre-mRNA splicing and gene expression.Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone miceMyocardin regulates vascular response to injury through miR-24/-29a and platelet-derived growth factor receptor-βIdentification of an internalising peptide in differentiated Calu-3 cells by phage display technology; application to gene delivery to the airways.Mutation in KERA identified by linkage analysis and targeted resequencing in a pedigree with premature atherosclerosis.Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation.Viral cross-class serpin inhibits vascular inflammation and T lymphocyte fratricide; a study in rodent models in vivo and human cell lines in vitro.Hematopoietic sphingosine 1-phosphate lyase deficiency decreases atherosclerotic lesion development in LDL-receptor deficient miceIdentification of a novel CD40 ligand for targeted imaging of inflammatory plaques by phage display.Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion developmentCirculating immunoglobulins are not associated with intraplaque mast cell number and other vulnerable plaque characteristics in patients with carotid artery stenosis.Myocardin regulates vascular smooth muscle cell inflammatory activation and diseaseCXCR4 blockade induces atherosclerosis by affecting neutrophil functionHck/Fgr Kinase Deficiency Reduces Plaque Growth and Stability by Blunting Monocyte Recruitment and Intraplaque Motility.Hematopoietic G-protein-coupled receptor kinase 2 deficiency decreases atherosclerotic lesion formation in LDL receptor-knockout mice.Viral serine protease inhibitors as anti-atherosclerotic therapy.Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile.Myocardial regeneration by transplantation of modified endothelial progenitor cells expressing SDF-1 in a rat model.Mast cells: pivotal players in cardiovascular diseases.The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics.Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.The serpin solution; targeting thrombotic and thrombolytic serine proteases in inflammation.Anti-apoptotic serpins as therapeutics in cardiovascular diseases.The impact of mast cells on cardiovascular diseases.Acute and chronic psychological stress as risk factors for cardiovascular disease: Insights gained from epidemiological, clinical and experimental studies.Mast cells in human and experimental cardiometabolic diseases.A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancyIncreased Plasma IgE Accelerate Atherosclerosis in Secreted IgM Deficiency.Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events.Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels.Deficiency of the TLR4 analogue RP105 aggravates vein graft disease by inducing a pro-inflammatory responseMast cells mediate neutrophil recruitment during atherosclerotic plaque progression.Uremia does not affect neointima formation in miceProtease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury: potential role in pulmonary fibrosis.RP105 deficiency attenuates early atherosclerosis via decreased monocyte influx in a CCR2 dependent manner.Leukocyte Bim deficiency does not impact atherogenesis in ldlr -/- mice, despite a pronounced induction of autoimmune inflammation.Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation.T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis.Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis
P50
Q26995160-FD5C5972-C589-4F91-85BF-23974BB0E9DDQ27328830-C941CD48-DB50-45E1-9D53-1F5B6F1F776FQ28579311-C86DCCA3-CBC4-4FF3-AD8B-5F13E4A08CFFQ28585806-1B499DA9-0B46-4E0A-8EC8-C58FE9D4B77AQ33203878-5190312D-C0E1-4716-BA97-3129BA801955Q33690049-BEDAA6A8-0E9E-4623-8FCA-5DB1C66E1197Q33882610-18C5D0E8-90A7-4F19-9D74-D20C0B94CAFBQ34437925-8BC8FEA7-F3B3-43A0-A948-CCF3871CB796Q34735060-125DCD0F-B278-4E75-B08E-33DDA64D5637Q34879458-FAFD39A0-31E8-492C-B3BC-CCFEDCA72CCAQ35077942-38E8E705-192B-4370-9CA2-64EC99819F0DQ35106514-1779F14E-4462-41EF-A8F5-22C5D5E28433Q35323782-CEBFDED7-060E-4767-BC33-12FFA8917FD9Q35565559-F0C504AE-AA19-4231-9759-1B6B33832E52Q35949916-6F053AF1-E3CA-44B9-A188-EBF3D0C1BBBFQ36482911-23BC8C83-08E0-45D9-ADFB-D1A3DEF468FAQ36923107-26587751-E13E-47EE-88B2-348338EBB58BQ37001999-F758D192-0C41-43A7-8528-C9F99898EF15Q37296208-7EF601D4-CA2D-49D0-BAD0-B1E895B8A8E1Q37638250-2D635332-AC42-43B8-B13B-4CF497898F9CQ37669985-92A44EA6-AA9E-4539-98FC-3F5538BCED16Q37671303-C9197B9D-F787-4E5F-97D7-939242BC2233Q38132453-26372D71-06EE-476D-B00F-00D5DD659C4CQ38132454-E144C5C6-897B-4E37-99C4-30FBB84D1FD3Q38470071-EA1C3057-3DAE-4FA2-BF4A-330A69C0A0E7Q38563397-15505999-52A4-418A-92C5-F217F280D395Q38563903-428D6B20-156F-4171-A081-079390BE1117Q38936733-12A6E6D9-D6B7-4D10-A4CE-0D474D9B3422Q39141719-89EE9225-F704-4FBE-894F-31A163F4AEAAQ39404175-83243D25-BFAD-4127-814E-F7B389560EC6Q39624057-2143D85E-BD9F-4BDC-9FD6-E79EB35D10DEQ39940427-EF988CCD-AFB8-4620-8CFF-3FD7413F0152Q40848443-DFCE7D9D-1B56-412B-8B5E-159F0DA0F6A2Q41140912-782F52EA-311E-4AEA-B37C-355676A88F72Q41459860-CB084F5E-59E6-4ABD-8585-05730DAF1B8EQ41611679-D35E3C51-DD6D-41AD-B362-805F7481363DQ41890791-F72FB285-DBC0-4C1A-B8E9-CAE5EDF89D36Q42216851-F84F0E7B-22A5-48B2-89CD-5DC3DBB0D8C5Q42273320-070F13EC-C3DB-4A46-A927-8D201BA0BC6BQ42288906-44C8AC8B-4641-4862-9A3D-50D1A432BA87
P50
description
Nederlands onderzoekster
@nl
hulumtuese
@sq
researcher
@en
հետազոտող
@hy
name
Ilze Bot
@ast
Ilze Bot
@en
Ilze Bot
@es
Ilze Bot
@nl
Ilze Bot
@sl
type
label
Ilze Bot
@ast
Ilze Bot
@en
Ilze Bot
@es
Ilze Bot
@nl
Ilze Bot
@sl
altLabel
I. Bot
@nl
prefLabel
Ilze Bot
@ast
Ilze Bot
@en
Ilze Bot
@es
Ilze Bot
@nl
Ilze Bot
@sl
P106
P1153
35569879300
P21
P31
P496
0000-0002-1242-1959
P569
2000-01-01T00:00:00Z
P735
P7449
PRS1302039